At the news
? BULLISHIMPACT 7/10 PRESS-RELEASE filed Apr 13, 2026 at 01:00 ET
Regeneron and Sanofi announced European Commission approval of Dupixent for children aged 2 to 11 years with moderate-to-severe chronic spontaneous urticaria (CSU), expanding its label to younger patients. This marks the first targeted therapy for this age group in the EU and strengthens Dupixent's position in type 2 inflammation-driven diseases.
- European Commission approved Dupixent for children 2 to 11 years with CSU who are unresponsive to antihistamines and naïve to anti-IgE therapy.
- Approval based on LIBERTY-CUPID trial program, including extrapolated adult efficacy data and pediatric safety/efficacy from CUPIDKids trial.
- Dupixent is now approved for children under 12 across four chronic type 2 inflammatory diseases.
- U.S. supplemental Biologics License Application (sBLA) for this population is under review.
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access